Acrux Limited
ACRASXLog in to unlock analysis summary free on one stock of your choice.
Log in to unlock detailed analysis free on one stock of your choice.
| AUD, millions | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | 4 | 1 | 5 | 8 |
| Gross Profit | 4 | 1 | 1 | 8 |
| Operating Income | -2 | -9 | -9 | -3 |
| Net Income | -1 | -6 | -6 | -1 |
Acrux Limited, together with its subsidiaries, develops and commercializes topically applied pharmaceutical products in Australia, the United States, Europe, and internationally. The company offers Dapsone 7.5% and 5% gels for the treatment of acne vulgaris; Nitroglycerine 0.4% ointments for the treatment of moderate to severe pain associated with chronic anal fissure; Lidocaine and Prilocaine creams USP 2.5% for local analgesia and pre-treatment for infiltration anesthesia; and estradiol transdermal sprays for women for the treatment of moderate to severe hot flushes associated with menopause under the Lenzetto and Evamist brand names. It also provides laboratory and product development services, including in vitro release testing; formulation development; stability and quality check; analytical; generic and pharma development; regulatory; project management and technology transfer; consulting; and co-development services. The company was incorporated in 1998 and is based in West Melbourne, Australia.